- Amgen recently reported positive Phase 3 results for a subcutaneous, on-body injector version of TEPEZZA in moderate-to-severe active Thyroid Eye Disease, showing a statistically significant 77% proptosis response rate over 24 weeks versus placebo with a safety profile broadly in line with the existing IV formulation.
- This progress toward a more convenient delivery option could be important for patient adoption and may influence how Amgen’s thyroid eye disease franchise competes against emerging alternatives.
- Next, we’ll examine how the successful TEPEZZA on-body injector Phase 3 results might influence Amgen’s investment narrative and future growth drivers.
Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
Amgen Investment Narrative Recap
To own Amgen, you have to believe its diversified portfolio and late‑stage pipeline can offset pricing pressure and biosimilar erosion, while funding heavy R&D and manufacturing spend. The TEPEZZA on‑body injector data is directionally positive, but it does not fundamentally change the near‑term focus on defending key franchises against biosimilars and managing margin pressure from higher R&D and capital expenditures.
Among recent announcements, the new VESALIUS‑CV subgroup results for Repatha are especially relevant. They reinforce Amgen’s push in chronic, high‑burden cardiovascular disease, which sits alongside TEPEZZA in the broader narrative that specialty biologics and outcomes‑focused therapies may drive volume growth. Together, these kinds of data points help frame how new indications and formulations could matter more to Amgen’s long‑term revenue mix than any single product update.
Yet, against this progress, investors should also weigh the growing risk that biosimilar competition and pricing pressure could...
Read the full narrative on Amgen (it's free!)
Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028.
Uncover how Amgen's forecasts yield a $350.03 fair value, in line with its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming Amgen could reach about US$44.4 billion in revenue and US$13.1 billion in earnings by 2029, so positive TEPEZZA OBI data may either support that view or force a rethink of how much of that upside you personally find realistic.
Explore 3 other fair value estimates on Amgen - why the stock might be worth just $350.03!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Amgen research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.
Seeking Other Investments?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com